| ▲ | megaman821 7 hours ago | |
I can't remember the source, but I think this only rules out small-dose, oral. There will still be a trial with large-dose, injectable. | ||
| ▲ | Mariehane 3 hours ago | parent | next [-] | |
Will there be a large-dose trial? I imagine that’s going to be more difficult, as the weight-loss effect of GLP-1 means you cant include frail patients in your target group. And GLP-1 at high doses also has some unfavourable side-effects: nausea, vomiting, diarrhea, constipation. | ||
| ▲ | burnt-resistor 5 hours ago | parent | prev [-] | |
For reference in typical maintenance doses: - Rybelsus (type-2 diabetes; oral semaglutide 14 mg/day; much less bioavailability) - Wegovy (obesity; injectable semaglutide 2.4 mg/wk) - Ozempic (type-2 diabetes; injectable semaglutide 1.0 mg/wk) | ||